Publications by authors named "Bhumesh Tyagi"
Role of Itolizumab in the Treatment of COVID-19 Patients, Admitted to ICU at a Tertiary Care Hospital.
J Assoc Physicians India
October 2022
Background: Clinical studies have correlated severe deterioration of COVID-19 patients due to excessive and uncontrolled production of cytokines. There is a pressing need to explore therapies, which could prevent the cytokine storm rather than terminating it.
Aims And Objectives: The aim of the study is to evaluate the effect of itolizumab on clinical outcomes of patients with moderate-severe COVID-19 disease admitted to ICU.
Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver diseases characterized by the presence of ectopic fat in the liver and steatosis, which cannot be explained by alcohol consumption. The association between NAFLD and type 2 diabetes mellitus (T2DM) is well established. As liver fibrosis progresses in a patient with NAFLD, insulin resistance (IR) increases and may worsen diabetes control.
View Article and Find Full Text PDFArticle Synopsis
- SARS-CoV-2 emerged in December 2019, causing COVID-19 with varying severity among patients linked to systemic inflammation and inflammatory markers like CRP and interleukin-6.
- The study aimed to correlate COVID-19 severity with inflammatory markers and CT severity scores to find optimal cut-off values indicating disease severity.
- Conducted as a retrospective observational study with 84 ICU patients, results showed 54 survivors and 30 non-survivors, establishing a significant relationship between clinical severity and inflammatory indicators.